Amylyx Pharmaceuticals is one heck of an encore.
On March 30, the Food and Drug Administration is bringing together outside experts in neurology to review an experimental drug from Amylyx for the treatment of amyotrophic lateral sclerosis, or ALS. The hearing is expected to be closely watched by ALS patients and their advocates, given the significant need for new treatments for the disease.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
